Device Trial Radar · NCT07941024
H.A.L.T. MAX Spectacle Lenses for High Myopia Control
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
112
Planned (sponsor's estimate)
Start
Nov 15, 2026
Primary completion
May 15, 2029
Study completion May 15, 2029
Sponsor
- Lead sponsor
- Shanghai Eye Disease Prevention and Treatment CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 7 years, up to 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is intended to focus on children aged 7-14 years with high myopia and to use a 2-year, single-arm, prospective design in which participants wear H.A.L.T. MAX lenses for at least 12 hours per day for 2 consecutive years. By comparing changes in refractive error and other indicators, the study will evaluate the efficacy, safety, and wearing compliance of H.A.L.T. MAX lenses in delaying myopia progression in children with high myopia, thereby providing scientific evidence for public health efforts to delay myopia progression in highly myopic populations and for the formulation and implementation of programs to address the risk of blindness and visual impairment caused by high myopia.
Conditions
- High Myopia
Interventions
H.A.L.T. MAX spectaclesDevice
Wearing H.A.L.T. MAX spectacles for at least 12 hours a day over 2 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SER changeTime frame: 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.